Transgene shares surged 20% in early Paris trading after the French biotechnology company reported positive Phase 1 trial data for TG4050, an individualised vaccine for high-risk head and neck cancer. Developed with Japan’s NEC Corp, the vaccine uses AI (artificial intelligence) technology to select patient-specific tumour targets after surgery and chemoradiotherapy. All 16 patients who received TG4050 remained disease-free, compared with three relapses among 16 patients in the control arm. Kempen analyst Chiara Montironi said longer follow-up produced a "robust dataset" supporting the vaccine’s potential to prevent relapse, although study authors said the small number of patients and events could not establish a statistically significant benefit. Transgene expects Phase 2 immunological data in the second half of 2026 and two-year efficacy data in the first quarter of 2028. The move follows investor enthusiasm for other personalised cancer-vaccine programmes, including Moderna, whose shares more than doubled after melanoma-vaccine data showed reduced recurrence or mortality risk.